HIGHLIGHTS
- who: Rui Kitadai from the Department of Breast and Medical Oncology, National Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan have published the research: Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study, in the Journal: (JOURNAL)
- what: Second-line chemotherapy may be an option for patients with refractory MPeM, especially those who have completed 6 cycles of cisplatin or carboplatin plus pemetrexed as first-line chemotherapy.
- future: These findings suggest that longer first-line chemotherapy may be recommended for patients in good general condition . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.